Of the mutations assessed, P29S and A159V were identified as strong activators for both EGFR and MAPK pathways, which are key pathways driving HNSCC tumorigenesis [26,27,28] (Figure 2E). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.